Dr. Erika Augustine, MD
NPI: 1346408556
Total Payments
$52,760
2024 Payments
$400.00
Companies
4
Transactions
47
Payment Breakdown by Category
Other$19,100 (36.2%)
Research$18,000 (34.1%)
Education$7,139 (13.5%)
Consulting$5,600 (10.6%)
Travel$2,205 (4.2%)
Food & Beverage$716.46 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,000 | 12 | 34.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,100 | 7 | 26.7% |
| Education | $7,139 | 10 | 13.5% |
| Consulting Fee | $5,600 | 4 | 10.6% |
| Grant | $5,000 | 1 | 9.5% |
| Travel and Lodging | $2,205 | 8 | 4.2% |
| Food and Beverage | $716.46 | 5 | 1.4% |
Payments by Type
General
$34,760
35 transactions
Research
$18,000
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PTC Therapeutics, Inc. | $25,600 | 17 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $16,560 | 25 | $0 (2020) |
| Amicus Therapeutics, Inc. | $5,600 | 4 | $0 (2021) |
| Biogen, Inc. | $5,000 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $400.00 | 1 | PTC Therapeutics, Inc. ($400.00) |
| 2023 | $5,100 | 2 | PTC Therapeutics, Inc. ($5,100) |
| 2022 | $12,500 | 9 | PTC Therapeutics, Inc. ($12,500) |
| 2021 | $6,800 | 5 | PTC Therapeutics, Inc. ($6,200) |
| 2020 | $9,233 | 5 | Amicus Therapeutics, Inc. ($5,000) |
| 2019 | $423.93 | 1 | BioMarin Pharmaceutical Inc. ($423.93) |
| 2018 | $13,303 | 23 | BioMarin Pharmaceutical Inc. ($13,303) |
| 2017 | $5,000 | 1 | Biogen, Inc. ($5,000) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/24/2024 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | ||||||
| 09/01/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 04/26/2023 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 12/07/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $800.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 11/09/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $2,200.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 11/09/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | ||||||
| 09/21/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 09/21/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 06/08/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | ||||||
| 05/18/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | ||||||
| 03/16/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,400.00 | Research |
| Study: EVALUATION OF THE EFFICACY AND SAFETY OF PTC299 IN HOSPITALIZED SUBJECTS WITH COVID-19 (FITE19) | ||||||
| 02/02/2022 | PTC Therapeutics, Inc. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: EVALUATION OF THE EFFICACY AND SAFETY OF PTC299 IN HOSPITALIZED SUBJECTS WITH COVID-19 (FITE19) | ||||||
| 12/01/2021 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| 10/13/2021 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| 07/28/2021 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| 06/09/2021 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| 01/05/2021 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/02/2020 | PTC Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| 08/11/2020 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 07/14/2020 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 05/05/2020 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 05/04/2020 | BioMarin Pharmaceutical Inc. | Brineura (Biological) | Education | In-kind items and services | $2,833.09 | General |
| Category: CLN 2 | ||||||
| 10/23/2019 | BioMarin Pharmaceutical Inc. | Brineura (Biological) | Education | In-kind items and services | $423.93 | General |
| Category: CLN 2 | ||||||
| 11/03/2018 | BioMarin Pharmaceutical Inc. | Brineura (Biological) | Food and Beverage | In-kind items and services | $113.05 | General |
| Category: CLN 2 | ||||||
| 11/02/2018 | BioMarin Pharmaceutical Inc. | Brineura (Biological) | Food and Beverage | In-kind items and services | $164.14 | General |
| Category: CLN 2 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | PTC Therapeutics, Inc. | $12,000 | 7 |
| EVALUATION OF THE EFFICACY AND SAFETY OF PTC299 IN HOSPITALIZED SUBJECTS WITH COVID-19 (FITE19) | PTC Therapeutics, Inc. | $3,200 | 2 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | PTC Therapeutics, Inc. | $2,400 | 2 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | PTC Therapeutics, Inc. | $400.00 | 1 |
About Dr. Erika Augustine, MD
Dr. Erika Augustine, MD is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2008. The National Provider Identifier (NPI) number assigned to this provider is 1346408556.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erika Augustine, MD has received a total of $52,760 in payments from pharmaceutical and medical device companies, with $400.00 received in 2024. These payments were reported across 47 transactions from 4 companies. The most common payment nature is "" ($18,000).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Rochester, NY
- Active Since 05/26/2008
- Last Updated 06/05/2012
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1346408556
Products in Payments
- Brineura (Biological) $16,560
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Rochester
Jonathan Mink, Md, Phd, MD, PHD
Neurology with Special Qualifications in Child Neurology — Payments: $92,029
Neurology with Special Qualifications in Child Neurology $92,029
Dr. Yuliya Snyder, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $8,586
Neurology with Special Qualifications in Child Neurology $8,586
Jennifer Nguyen, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $4,347
Neurology with Special Qualifications in Child Neurology $4,347
Duygu Selcen, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $2,323
Neurology with Special Qualifications in Child Neurology $2,323
Dr. Evelyn Berman, M.d. M.s, M.D. M.S
Neurology with Special Qualifications in Child Neurology — Payments: $1,711
Neurology with Special Qualifications in Child Neurology $1,711
John Bodensteiner, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $1,565
Neurology with Special Qualifications in Child Neurology $1,565